文献速递临床试验与 GCP基础与转化研究

左甲状腺素替代治疗对慢性收缩性心衰伴亚临床甲减患者运动能力疗效与安全性的多中心开放标签随机平行组试验方案(ThyroHeart-CHF)

Efficacy and safety of levothyroxine (L-T4) replacement on the exercise capability in chronic systolic heart failure patients with subclinical hypothyroidism: Study protocol for a multi-center, open label, randomized, parallel group trial (ThyroHeart-CHF).
PubMed 文献 · Trials · 2019-02-19

本研究为多中心、开放标签、随机平行组试验,拟纳入≥18岁、NYHA II-III级、LVEF≤40%且合并亚临床甲减(TSH>4.78μIU/ml且<10μIU/ml,FT4正常)的慢性收缩性心衰患者,1:1随机接受左甲状腺素替代联合标准心衰治疗或仅标准治疗。左甲状腺素起始12.5μg每日一次,滴定至TSH正常。主要终点为24周与基线六分钟步行试验距离差值。

要点

  • 左甲状腺素起始12.5μg每日一次,滴定至TSH正常范围。
  • 主要终点为24周与基线六分钟步行试验距离差值。
  • 纳入标准包括TSH>4.78μIU/ml且<10μIU/ml、FT4在参考范围。

核心结论

  • 该试验旨在比较甲状腺激素补充对慢性心衰合并亚临床甲减患者的疗效与安全性。

研究设计与样本

  • 多中心、开放标签、随机、平行组试验,从五个中心心内科筛选符合条件患者。
  • 纳入标准:≥18岁、NYHA II-III级收缩性心衰、LVEF≤40%、亚临床甲减(TSH>4.78μIU/ml且<10μIU/ml,FT4在参考范围)。
  • 合格患者按1:1随机接受左甲状腺素替代联合标准心衰治疗或仅标准心衰治疗。

关键数值与推荐

  • 左甲状腺素起始剂量12.5μg每日一次,滴定至TSH在正常范围。
  • 主要终点为24周与基线六分钟步行试验距离差值。
  • 次要终点包括24周与基线血浆NT-proBNP水平、血脂谱、NYHA分级变化、心血管死亡、再住院、超声心动图和心脏磁共振指标及MLHFQ结果差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Subclinical hypothyroidism is a common condition in patients with heart failure and is defined as elevated serum thyroid hormone (TSH) with normal circulating free thyroxine (FT4). Evidence on the effect of thyroid hormone treatment is lacking. We designed a randomized controlled trial to compare the efficacy and safety of thyroid hormone supplementation in patients with chronic heart failure complicated with subclinical hypothyroidism. METHODS/DESIGN: Eligible participants were identified from the cardiology units of five study centers based on the following criteria: 18 years or older, systolic heart failure with NewYork Heart Association (NYHA) class II-III, left ventricular ejection fraction ≤ 40%, and subclinical hypothyroidism (TSH > 4.78μIU/ml, < 10 μIU/ml + FT4 level within reference range). Eligible patients will be randomly assigned in a 1:1 manner to receive thyroxine replacement therapy plus standard chronic heart failure (CHF) treatment or only standard CHF therapy. Levothyroxine will be administered at an initial dose of 12.5 μg once daily and will be titrated until TSH is within the normal range. The primary endpoints include the difference in distance of the six-minute walk test between 24 weeks and baseline. The secondary endpoints include differences in plasma NT-proBNP levels and serum lipid profiles, changes in the NYHA classification, cardiovascular death, re-hospitalization, differences in echocardiographic and cardiac magnetic resonance imaging measures, and Minnesota Living With Heart Failure Questionnaire (MLHFQ) results between 24 weeks and baseline. DISCUSSION: ThyroHeart-CHF is designed as a prospective, multi-center, randomized, controlled clinical trial to study the efficacy and safety of thyroid hormone supplementation in patients with chronic heart failure complicated with subclinical hypothyroidism. The study findings will have significant implications for discovering the new therapeutic targets and methods of heart failure. TRAIL REGISTRATION: ClinicalTrials.gov, NCT03096613 . Registered on 30 March 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Zhang X, Wang WY, Zhang K, et al. Efficacy and safety of levothyroxine (L-T4) replacement on the exercise capability in chronic systolic heart failure patients with subclinical hypothyroidism: Study protocol for a multi-center, open label, randomized, parallel group trial (ThyroHeart-CHF). Trials. 2019. PMID: 30782213. doi:10.1186/s13063-019-3219-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。